Initial screening excluded subjects with obvious causes for bronchial hyperreactivity including smoking, atopy, or recent viral respiratory infection. The remaining 84 subjects underwent the following measurements: (1) physical examination; (2) spirometric testing and measurement of static lung volumes using a Jaeger Masterlab and slow vital capacity measured by an expiratory manoeuvre with the best of three reproducible measurements being recorded; (3) measurement of the effect of exercise challenge on the spirometric data as previously described.9 Each patient underwent spirometric tests followed by 10 minutes running on a treadmill (Quinton) reaching 90(5)% of maximal predicted heart rate. Spirometric testing was repeated 15 minutes later and a drop of ) 15% in FEV, was considered significant; (4) methacholine challenge performed according to a modification of Chai's method, not using a dosimeter.'0 A Devilbis (645) nebuliser delivering compressed air at a rate of 6 1/ min was used for inhalation challenge. Each patient inhaled increasing concentrations of methacholine (0 07, 0-15, 0-3, 0-6, 1-5, 3, 6, 12, 25 mg/ml), each of which was inhaled by five inspirations from FRC to TLC. Spirometric parameters were measured at baseline and repeated 1-5 minutes after each dose of methacholine until at least two technically correct manoeuvres were obtained; the better value was recorded. The concentration inducing a 20% drop in FEV, was calculated from the semilogarithmic dose-response curve. The provocation was continued until the last dose in all subjects.
Bronchial hyperreactivity to histamine and methacholine is a fundamental feature in both patients with bronchial asthma' and those with chronic obstructive pulmonary disease (COPD.2 In patients with COPD the level of bronchial hyperreactivity is partially determined by the initial extent of airway obstruction. Ramsdale et aP' found a correlation between the initial forced expiratory volume in one second (FEVy) and the degree of bronchial hyperreactivity in these patients.
Most studies performed on asthmatic subjects report no correlation between the extent of bronchial hyperreactivity and the baseline airway calibre. 4 Initial screening excluded subjects with obvious causes for bronchial hyperreactivity including smoking, atopy, or recent viral respiratory infection. The remaining 84 subjects underwent the following measurements: (1) physical examination; (2) spirometric testing and measurement of static lung volumes using a Jaeger Masterlab and slow vital capacity measured by an expiratory manoeuvre with the best of three reproducible measurements being recorded; (3) measurement of the effect of exercise challenge on the spirometric data as previously described.9 Each patient underwent spirometric tests followed by 10 minutes running on a treadmill (Quinton) reaching 90(5)% of maximal predicted heart rate. Spirometric testing was repeated 15 minutes later and a drop of ) 15% in FEV, was considered significant; (4) methacholine challenge performed according to a modification of Chai's method, not using a dosimeter.'0 A Devilbis (645) nebuliser delivering compressed air at a rate of 6 1/ min was used for inhalation challenge. Each patient inhaled increasing concentrations of methacholine (0 07, 0-15, 0-3, 0-6, 1-5, 3, 6, 12, 25 mg/ml), each of which was inhaled by five inspirations from FRC to TLC. Spirometric parameters were measured at baseline and repeated 1-5 minutes after each dose of methacholine until at least two technically correct manoeuvres were obtained; the better value was recorded. The concentration inducing a 20% drop in FEV, was calculated from the semilogarithmic dose-response curve. The provocation was continued until the last dose in all subjects.
Each subject participated in three study days at the same time of the day within a two week period. On day 1 baseline pulmonary function tests and response to salbutamol were measured, on day 2 exercise challenge was performed, and on day 3 a methacholine challenge was performed. Subjects who demonstrated bronchial hyperreactivity underwent skin tests (prick) with environmental allergens (dust, mite, cockroach, mixed moulds, mixed grasses, mixed trees, dog, cat, with histamine and saline as control). These subjects also had an additional bronchial hyperreactivity evaluation by measuring peak expiratory flow rates (mini Wright) twice a day for a week. As a control group 37 young healthy men were included in the study (group B). All were employed by the hospital and had volunteered for the study. None were smokers, and none had atopy nor recent viral respiratory infections. They all underwent the same evaluations as those in group A.
The study was approved by our local Helsinki Ethical Committee. An interesting feature of the airway responses in both groups was the fact that at certain points all the subjects reached a plateau, after which no further drop in FEV1 was observed (figure). The rates of bronchial hyperreactivity in both groups and the shape of the doseresponse curve were not significantly different. Two of the subjects in group A and one in group B had positive skin tests (> 5 mm weal diameter), two to mite, and one to grass mix; they denied atopic symptoms. The small decrease of FEVI/VC% in our symptomatic subjects had no effect on bronchial hyperreactivity. Interestingly, our subjects showed a particular dose-response pattern following methacholine, with a relatively small drop in FEV,, previously shown by Woolcock et al to occur in healthy subjects. 7 We conclude that the low FEV,/VC% ratios of our group of otherwise normal subjects was not associated with any evidence of disease. Bronchial hyperreactivity does not occcur more frequently in this group of subjects than in healthy controls, but when it is found a plateau of FEVI is seen that is similar to the normal bronchoconstrictor response to methacholine and unlike that of asthmatics. Low FEV,/VC% with normal values of VC in asymptomatic subjects does not merit special investigation for airway disorders.
